肿瘤治疗相关血小板减少症危险因素研究进展  

Advances in research on risk factors for thrombocytopenia associated with tumor therapy

作　　者：常丽 孙素芹[2] 张良[2] 刘雪梅 Chang Li;Sun Suqin;Zhang Liang;Liu Xuemei(Harbin Chest hospital,Harbin 150056,China;Department of Respiratory Medicine,Hanan Branch,the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine 150060,China)

机构地区：[1]哈尔滨市胸科医院,黑龙江哈尔滨150056 [2]黑龙江中医药大学附属第二医院哈南分院,黑龙江哈尔滨150060

出　　处：《青岛医药卫生》2023年第5期361-365,共5页Qingdao Medical Journal

基　　金：黑龙江省卫生健康委科研课题(项目编号:2020-059)。

摘　　要：肿瘤治疗相关血小板减少症(Cancer Therapy-Related Thrombopenia, CTRT)可导致肿瘤患者出血、输血,方案调整,治疗延后、中断等不良后果,严重影响抗肿瘤疗效及疾病转归。CTRT危险因素包括局部治疗因素、全身治疗因素、患者自身因素和肿瘤相关因素,对多种危险因素并存的患者适当调整治疗方案,可能降低CTRT的发生率及严重程度,从而保证肿瘤治疗的连续性,提高疗效并延长总生存。笔者对CTRT各种危险因素的研究进展进行综述,以期帮助临床综合评估,为筛选最有利于患者的治疗方案提供参考。Thrombocytopenia related to tumor treatment can lead to bleeding,blood transfusion,program adjustment,delayed treatment,interruption and other adverse consequences,which seriously affects the anti-tumor efficacy and disease outcome.There are a variety of risk factors,involving local treatment factors,systemic treatment factors and patients′own factors.Appropriate adjustment of the treatment plan for patients with multiple risk factors may reduce the incidence and severity of thrombocytopenia caused by tumor treatment,so as to ensure the continuity of tumor treatment,improve the efficacy and extend it.Always survive.The author reviews the research progress of various risk factors related to thrombocytopenia related to tumor treatment,in order to help comprehensive clinical evaluation and provide reference for screening the treatment plan that is most conducive to patients.

关 键 词：肿瘤治疗相关 血小板减少症 危险因素 

分 类 号：R730.5[医药卫生—肿瘤]